You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes

    SBC: BIONIKS            Topic: NIAMS

    DESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Polymer-Based Micro-sensor for Radiation Detection and Measurement

    SBC: SEACOAST SCIENCE, INC.            Topic: NIEHS

    Project Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. An Agent-Based Modeling Platform for Environmental Biotechnology

    SBC: MICROVI BIOTECH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant Hazardous compounds in waters and soils are subject to a complex dynamic web of interactions among physical chemical and biological constituents in the natural environment Computational modeling has been proven indispensable to hazardous substances remediation particularly integrated modeling of pollutant hydrogeological fate and transport For the first t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Fast Track Insulin remains the primary and often the only treatment for type diabetes mellitus T D However it is associated with chronic iatrogenic hyperinsulinemia secondary hyperlipidemia higher incidence and severity of cardiovascular complications and life threatening hypoglycemia events A higher mortality vs due to cardiovascular ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A universal vaccine for the prevention of meningococcal meningitis in Africa

    SBC: OMVAX INC            Topic: R

    For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergy

    SBC: ABWIZ BIO INC            Topic: NIAID

    DESCRIPTION provided by applicant The prevalence of food allergy has been dramatically increasing for the last few decades Food Allergy and Anaphylaxis Network www foodallergy org estimates that up to million Americans have food allergies Six to eight percent of children under the age of three have food allergies and nearly four percent of adults have them Signs and symptoms of food all ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government